Health
Retatrutide Trial Shows Promising Weight-Loss Results
Retatrutide, a new obesity drug, showed significant weight loss in trials. The triple-hormone agonist is the first of its kind to reach phase 3 clinical testing.
Coverage timeline — 2 articles
Scientific American
The experimental weight-loss drug is a triple agonist and the first of its kind to reach a phase 3 clinical trial
2026-09-29 22:01 UTC
Ars Technica
Retatrutide is a triple-hormone obesity drug simulating GLP-1, GIP, and glucagon.
2026-09-29 22:30 UTC